Cargando…
The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation
The class I phosphoinoside-3-kinases (PI3Ks) are important enzymes that relay signals from cell surface receptors to downstream mediators driving cellular functions. Elevated PI3K signaling is found in B cell malignancies and lymphocytes of patients with autoimmune disease. The p110δ catalytic isofo...
Autores principales: | Chiu, Honyin, Mallya, Sharmila, Nguyen, Phuongthao, Mai, Annie, Jackson, Leandra V., Winkler, David G., DiNitto, Jonathan P., Brophy, Erin E., McGovern, Karen, Kutok, Jeffery L., Fruman, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491903/ https://www.ncbi.nlm.nih.gov/pubmed/28713374 http://dx.doi.org/10.3389/fimmu.2017.00747 |
Ejemplares similares
-
Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function
por: Chiu, Honyin, et al.
Publicado: (2021) -
Impact of the Smoothened Inhibitor, IPI-926, on Smoothened Ciliary Localization and Hedgehog Pathway Activity
por: Peluso, Marisa O., et al.
Publicado: (2014) -
The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018) -
Simplicity at the cost of predictive accuracy in diffuse large B‐cell lymphoma: a critical assessment of the R‐IPI, IPI, and NCCN‐IPI
por: Biccler, Jorne, et al.
Publicado: (2017) -
Health outcomes, education, healthcare delivery and quality – 3063. Cost-effectiveness of immunotherapy for children with atopic dermatitis
por: Derkach, Vladislava, et al.
Publicado: (2013)